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High Expression of EpCAM and 
Sox2 is a Positive Prognosticator of 
Clinical Outcome for Head and Neck 
Carcinoma
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Florian Simon1, Julius Shakhtour1, Brigitte Mack1, Gisela Kranz1, Darko Libl1, Martin Leu4, 
Markus A. Schirmer4, Martin Canis1, Claus Belka2,5, Horst Zitzelsberger2,6, Ute Ganswindt2,5, 
Julia Hess2,6, Mark Jakob1, Kristian Unger2,6 & Olivier Gires  1,2
Locally advanced head and neck squamous cell carcinomas (HNSCC) have limited prognosis due to 
frequent treatment failure. Currently, TNM-classification and human papillomavirus (HPV) infection are 
the sole clinical prognosticators of outcome. Tumor heterogeneity and stemness based on epithelial-
mesenchymal-transition reportedly associate with therapy resistance. The capacity of epithelial 
marker EpCAM (EpEX), stemness regulator Sox2 and mesenchymal marker vimentin to predict clinical 
outcome of HSNCC patients was assessed upon immunohistochemistry staining in two cohorts of 
HNSCC patients treated with surgery and adjuvant radio (chemo) therapy (n = 94) and primary radio 
(chemo) therapy (n = 94), respectively. Prognostic values with respect to overall, disease-free and 
disease-specific survival were assessed in uni- and multivariate cox proportional hazard models to 
generate integrated risk scores. EpEX, Sox2 and vimentin displayed substantial inter- and intratumoral 
heterogeneity. EpEXhigh and Sox2high predicted improved clinical outcome in the discovery cohort and 
in the HPV-negative sub-cohort. EpEXhigh and Sox2high were confirmed as prognosticators of clinical 
outcome in the validation cohort treated with definitive radio(chemo)therapy. Importantly, EpEXhigh 
identified patients with improved survival within the HPV-negative subgroup of the validation cohort. 
Hence, Sox2high and particularly EpEXhigh have potential as tools to predict clinical performance of 
HNSCC patients, foremost HPV-negative cases, in the frame of molecular-guided treatment decision-
making.
Head and neck squamous cell carcinomas (HNSCC) are typically induced by carcinogenic components of alcohol 
and tobacco or -primarily for oropharyngeal carcinomas- through infection with high-risk human papilloma-
viruses (HPV)1,2. Currently, three separate HPV-negative and further two biologically differing HPV-positive 
subtypes of HSNCC can be distinguished2. Despite aggressive treatment, HNSCC display dismal 5-year overall 
survival (OS) and disease-free survival (DFS) rates of less than 45%3. The clinical outcome including OS and 
DFS strongly depends on tumor size, locoregional spread, resection margins, extracapsular extension (ECE), 
lymphovascular invasion and systemic dissemination1. Accordingly, TNM classification is an accepted prognos-
tic factor for HNSCC that can serve to predict survival probabilities, but does not allow for a more differential, 
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adjusted, and personalized prediction of the outcome of tumor patients with similar TNM status. More subtle 
differences across patients that might impact on outcome are rather neglected by merely focusing on TNM clas-
sification, hence the need for valid biomarkers. HPV-status is currently the strongest available marker identifying 
HPV-positive HNSCC as distinct subgroup of HNSCC with prolonged OS, which is meanwhile implemented in 
a new TNM classification system for p16-positive oropharyngeal carcinomas4.
Owing to a long-lasting tobacco and nicotine abuse, frequently in conjunction with alcohol abuse, and to the 
high mutagenic potential of these prime risk factors associated with HNSCC, the mutational burden that eventu-
ally contributes to cellular heterogeneity is very high with an average of 130 mutations per tumor5,6. Heterogeneity 
contributes to the emergence of aggressive and treatment-resistant cell subsets through pre-existing subpopula-
tions in primary tumors7. Phenotypic changes along the epithelial-to-mesenchymal transition (EMT/MET) allow 
carcinoma cells to gradually and reversibly change phenotype from adhesive, stationary and proliferative cells 
(epithelial) to migratory, invasive and rather resting cells (mesenchymal)8–11. EMT is reported to increase cellu-
lar stemness, provide invasive features required for tumor progression, and enhance treatment resistance9,11,12. 
Accordingly, tumor-initiating cells in HNSCC can adopt either an epithelial/proliferative (E-type) or a mesen-
chymal/migratory (M-type) phenotype, where M-type cells within HNSCC cell lines and primary tumors bear 
enhanced therapeutic resistance13,14. However, a strict reliance of carcinoma cells on EMT to progress through 
the metastatic cascade and become treatment-resistant has been challenged in some entities such as pancreatic 
and lung cancers15,16. Accordingly, the central role of EMT in cancer progression has been intensely and contro-
versially discussed in recent years9,17,18.
In the present study, we analyzed the expression levels and patterns of EpCAM, Sox2 and vimentin in primary 
HNSCC for association with patient outcome. EpCAM is an epithelial cell marker involved in regulation of pro-
liferation and stem cell differentiation19–22. EpCAM down-regulation in mesodermally differentiating embryonic 
stem cells that undergo EMT is an early and necessary event in gastrulation22, which is likewise observed in par-
tial EMT occurring in cancer cells23–28. Sex-determining region Y-box 2 (Sox2) is a transcription factor required 
for stem cell pluripotency and reprograming of somatic cells to induced pluripotent stem cells29. Owing to ampli-
fication on chromosome 3q26, Sox2 is frequently over-expressed in carcinomas including HNSCC30. Vimentin is 
an intermediate filament expressed by mesenchymal cells and carcinoma cells that have undergone EMT, which 
is involved in the regulation of cell motility and invasion31.
On the basis of protein expression patterns, we have defined high expression of Sox2 (Sox2high) and of 
EpCAM (measured using antibodies against the extracellular domain EpEX; EpEXhigh) as prognostic factors for 
improved clinical outcome of HNSCC. EpEXhigh was a significant prognostic factor for overall, disease-free and 
disease-specific survival in HPV-negative patients of two independent cohorts with fundamentally different clin-
ical treatment. Hence, Sox2high and particularly EpEXhigh represent promising tools for improved stratification of 
HNSCC and, thus, for alternative therapeutic decision-making for patients with similar TNM status.
Results
EpEX, Sox2 and vimentin expression in the discovery HNSCC LMU cohort. Expression of epithe-
lial marker EpCAM (detected with antibodies specific for the extracellular domain EpEX), transcription factor 
Sox2 and mesenchymal marker vimentin was evaluated in consecutive kryo-conserved serial sections (5 µm) of 
biospecimens of the retrospective LMU cohort (Table 1, upper part, and Supplementary Table 1). EpCAM and 
vimentin mRNA levels are major determinants of epithelial differentiation and partial EMT in HNSCC, as was 
recently reported using single cell RNA-sequencing data32. Therefore, EpCAM and vimentin proteins represent a 
pair of potential markers for EMT in HNSCC, which should have opposing expression patterns in tumors.
Vimentin-expressing cells in the interstitium and infiltrating non-tumor cells were excluded from the anal-
yses based on their morphology combined with intense and homogeneous antigen expression. EpEX, Sox2 and 
vimentin were heterogeneously expressed in tumors, ranging from no expression (0), weak (1+), intermediate 
(2+), to strong expression (3+) and in normal mucosa (Fig. 1a–c). In normal mucosa, EpEX and Sox2 were 
expressed in cells of the stratum basale and stratum parabasale only, and Sox2 expression did not exceed an inter-
mediate (2+) level (Fig. 1a,b). Vimentin expression in normal mucosa was restricted to infiltrating mesenchymal 
cells and was up-regulated in tumor-adjacent mucosa with hyper- and/or dysplastic cells (Fig. 1c).
IHC scores, representing intensity and frequency of antigen expression from two to four sections of bio-
specimen, ranged from 0–300 with various combinations of intensities and percentages for all three antigens 
(Supplementary Table 1). Comparison of normal mucosa, tumor-adjacent mucosa, and tumors disclosed a strong 
and highly significant (p < 0.0001) up-regulation of EpEX in tumors with median IHC scores of 220 versus 60 and 
50 in tumor-adjacent and healthy mucosa, respectively (Fig. 1d). Sox2 expression was strongly and highly sig-
nificantly (p < 0.0001) up-regulated in tumors versus normal and tumor-adjacent mucosa (median IHC score of 
150 in tumors versus 0 in normal and tumor-adjacent mucosa), whereas vimentin expression showed a moderate 
induction in tumor-adjacent mucosa and tumors as compared to normal mucosa (p < 0.0001) (Fig. 1d).
An association of EpEX and Sox2 IHC scores with HPV-status was observed, where increased expres-
sion levels were shown for both in HPV-positive HNSCC (Table 1 and Fig. 1d). Vimentin did not show any 
HPV-associated difference in expression (Fig. 1d).
EpEX, Sox2 and vimentin expression patterns in HNSCC. Two major and two minor tumor expres-
sion patterns of EpEX, Sox2 and vimentin were observed in the LMU cohort: High expression of EpCAM and 
Sox2, but lack of vimentin expression (EpEX/Sox2+/vimentin− 43.01%), high expression of all three antigens 
(EpEX/Sox2/vimentin+ 35.48%), high expression of EpCAM and vimentin, but lack of Sox2 expression (EpEX/
vimentin+/Sox2− 7.53%) and high expression of EpCAM, but lack of Sox2 and vimentin expression (EpEX+/
Sox2/vimentin− 3.23%). Representative staining of all four major expression patterns on consecutive sections 
of tumor samples are shown in Fig. 2a. Significant positive correlation of Sox2 with EpEX (Fig. 2b; rho = 0.41, 
www.nature.com/scientificreports/
3SCIeNtIfIC REpoRts |  (2018) 8:14582  | DOI:10.1038/s41598-018-32178-8
p-value < 0.001) and a trend for a weak, negative correlation of Sox2 with vimentin was found (Fig. 2b; 
rho = −0.19, p-value = 0.062). Hence, epithelial marker EpCAM showed co-expression with reprogramming 
factor Sox2, but mesenchymal marker vimentin was independent from EpCAM expression and its expression 
negatively related to that of Sox2.
In order to further study the correlation of EpCAM, Sox2 and vimentin at the transcriptional level, mRNA 
expression data from HNSCC patients (n = 279) included in The Cancer Genome Atlas (TCGA) cohort were 
analyzed5. TCGA data confirmed a strong positive and significant correlation of EpCAM and Sox2 expres-
sion (rho = 0.64, p < 0.001). Furthermore, EpCAM and Sox2 negatively correlated with vimentin expres-
sion with rho = −0.25 (EpCAM, p < 0.001) and rho = −0.26 (Sox2, p < 0.001) values, respectively (Fig. 2c). 
Stratification according to the HPV-status (HPV-negative = 243 cases; HPV-positive = 36 cases) disclosed no 
correlation of EpCAM mRNA expression with HPV infection, whereas Sox2 and vimentin correlated posi-
tively (Mann-Whitney p-value = 7.9E-05) and negatively (Mann-Whitney p-value = 0.04008), respectively. 
Correlation of antigen expressions were only addressed in HPV-negative samples, owing to the limited number 
Variable LMU cohort
EpEx
p-value
Sox2
p-value
Vimentin
p-value
Gender Male Female
% 78.7 21.3 0.553 0.785 0.607
Age <50 50-69 ≥70
% 16.0 63.8 20.2 0.528 0.201 0.699
P16 Negative Positive n.p. Negative < Positive
Negative < 
Positive
% 51.1 30.9 18.1 0.007 0.020 0.725
T-Stage pT1-2 pT3-4 pTx
% 54.3 43.6 2.1 0.235 0.712 0.309
N-Stage N0 N+ Nx N0 < N+
% 35.1 63.8 1.1 0.113 0.006 0.498
M-Stage cM0 cM+ cMx
% 98.9 1.1 0 0.667 0.851 0.430
P-Stage Pn0 Pn1 Pnx Pn0 < Pn1
% 48.9 14.9 36.2 0.078 0.015 0.803
Smoking Status Never Former Current n.p
% 14.9 25.5 47.9 11.7 0.419 0.317 0.882
Localization Oral Cavity Oropharynx Hypopharynx & Larynx
OC < OP/
HP/Larynx
% 26.6 57.4 16.0 0.001 0.305 0.137
Variable Göttingen cohort EpExp-value
Sox2
p-value
Vimentin
p-value
Gender Male Female
% 83.0 17.0 0.369 0.888 0.639
Age <50 50-69 ≥70
% 21.3 67.0 11.7 0.508 0.206 0.11
P16 Negative Positive
% 52.1 47.9 0.459 0.107 0.556
T-Stage pT1-2 pT3-4
% 12.8 87.2 0.154 0.747 0.414
N-Stage N0 N+ N0 < N+
% 17.0 83.0 0.008 0.116 0.294
M-Stage cM0 cM+
% 89.4 10.6 0.591 0.690 0.403
Smoking Status Never Ever
% 19.1 80.9 0.512 0.854 0.360
Localization Oral Cavity Oropharynx Hypopharynx & Larynx
OC < OP/HP/
Larynx
% 31.9 40.4 27.7 0.135 0.004 0.814
Table 1. Clinical parameters of HNSCC LMU (upper) and Göttingen (lower) cohorts (each n = 94) including 
gender, age, p16 expression, TNM status, smoking habits, and tumor sub-localization. One way ANOVA 
(Kruskal-Wallis-Trial) was used to compare variables and biomarkers (EpEX, Sox2, Vimentin). Antigens 
differentially expressed at p < 0.05 are marked with the compared groups of variables and the orientation 
of differential expression (low “<” high) mentioned. OC = oral cavity, OP = oropharynx carcinoma, 
HP = hypopharynx carcinoma.
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of HPV-positive specimen. EpCAM and Sox2 positively correlated (rho = 0.633, p-value < 2.2E-16), EpCAM 
and vimentin negatively correlated (rho = −0.267, p-value = 2.5E-05), and Sox2 and vimentin negatively cor-
related (rho = −0.25, p-value = 7.69E-05). Stratification of patients within the TCGA cohort according to 
tumor size disclosed higher expression of EpCAM expression in bigger tumors (T-classification 3–4 versus 1–2) 
(Mann-Whitney p-value = 0.013), whereas Sox2 and vimentin expression did not correlate with tumor size. No 
correlation was observed between the three antigens and tumor grade of differentiation. In summary, expression 
patterns of EpCAM and Sox2 positively correlated at the mRNA level in a large independent HNSCC patient 
cohort, whereas vimentin showed an inverse expression pattern compared to that of EpCAM and Sox2.
Heterogeneous expression patterns of EpEX, Sox2 and vimentin were analyzed in further detail at the single 
cell level using immunohistochemistry and immunofluorescence staining. Frequent co-expression and simulta-
neous lack of EpEX and Sox2 was confirmed (Fig. 2d). Mutually exclusive expression of EpEX and vimentin was 
recurrently observed at the interface of the tumor area to interstitium. EpCAMlow/-/vimentin+ cells lined up as 
agglomerates within tumor protrusions (Fig. 2d,e left panel) and as islands of vimentin+ cells at the edge of large 
tumor areas (Fig. 2e, central panel). Small islands of tumor cells separated from the major tumor area frequently 
showed loss of EpCAM expression at the edges, which was linked to gain of vimentin expression (Fig. 2e, right 
panel), itself suggestive of partial EMT within tumors. EMT-related phenotypes co-existed in HNSCC samples 
with single cells displaying exclusive expression of epithelial marker EpCAM adjacent to cells characterized by 
complete lack of EpCAM and gain of mesenchymal marker vimentin (Fig. 2e, most right panel). Such differences 
in intratumoral sub-localization of antigen expression is in accordance with reports from Puram et al.32, who 
Figure 1. EpEX, Sox2 and vimentin expression in HNSCC and normal mucosas. (a–c) Shown are examples of 
EpEX (a), Sox2 (b) and vimentin (c) expression ranging from no (0), weak (1), intermediate (2) to strong (3) in 
HNSCC (upper panels; 200×), normal mucosas and tumor-adjacent mucosas (lower panels; 100×). EpCAM, 
Sox2 and vimentin staining is red-brown, nuclei and cytoplasm are counter-stained with hemalaun (blue). 
(n/d.: not detected). Tu: tumor; Int: interstitium. (d) Upper: IHC scores of EpEX, Sox2 and vimentin expression 
in normal mucosas, tumor-adjacent mucosas and HNSCC are displayed as violin plots including median 
(open circle), 1st and 3rd interquartile range, minima and maxima, and kernel density estimation. p-values are 
derived from unpaired Mann-Whitney testing. Lower: IHC scores of EpEX, Sox2 and vimentin expression in 
HPV-positive and –negative HNSCC are displayed as violin plots including median (open circle), 1st and 3rd 
interquartile range, minima and maxima, and kernel density estimation (n/d: not determined). P-values are 
derived from paired Student´s T-test following confirmation of normal distribution of data (Levene test).
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reported on a predominant partial EMT at the leading edges of tumors. These might represent tumor cells with 
increased capacity of delamination and local invasion of surrounding stromal tissue, and are thus of potential 
clinical importance.
In order to exclude that vimentin+ cells in tumor areas represented infiltrating non-tumor cells, selected tumor 
specimens were stained with vimentin- and either CD31- (endothelial cells), CD68- (monocytes/macrophages), 
or CD90-specific antibodies (fibroblasts), respectively. Vimentin+ cells did neither express CD31 nor CD90, but 
vimentin/CD68+ macrophages/monocytes were detected (Supplementary Fig. 1). However, vimentin+ tumor 
cells were morphologically distinguishable from infiltrating, vimentin-expressing monocytes/macrophages.
Association of EpEX, Sox2 and vimentin with clinical outcome. IHC scores for each single antigen 
were analyzed for association with clinical endpoints, in order to define potential prognostic factors. Stratification 
according to HPV-status confirmed improved OS and DFS for HPV+ patients, while no statistical difference 
was observed with respect to DSS (Fig. 3a). Threshold optimization was applied to IHC scores of all antigens to 
define optimal cut-offs for each clinical endpoint. Accordingly, patients were separated into groups of antigenhigh 
and antigenlow expressors, i.e. if their antigen expression was above or below calculated thresholds, respectively. 
Figure 2. EpEX, Sox2 and vimentin expression patterns in HNSCC. (a) Examples of the major four expression 
patterns of EpEX, Sox2 and vimentin are shown with according frequencies in percentages. All antigen-specific 
staining (200×) in consecutive sections are depicted in red-brown, while nuclei and cytoplasm are counter-
stained with hemalaun (blue). Tu: tumor; Int: interstitium. (b) IHC scores of EpEX, Sox2 and vimentin for 
HNSCC (n = 94) were plotted and displayed with linear regression curves, p-values and Spearman’s rank rho 
coefficient. (c) mRNA expression level z-scores for EpCAM, Sox2 and vimentin from The Cancer Genome 
Atlas (TCGA) HNSCC cohort (n = 279) were downloaded at cBioPortal and were depicted as an expression 
heat-map. Spearman correlation analysis results with rho coefficient and p-values are indicated. (d) EpEX, Sox2 
and vimentin expression in serial sections of HNSCC is depicted (400×). Examples of tumor cells with reduced 
EpCAM and increased vimentin expression are numbered (1 to 5). (e) Simultaneous immunofluorescence 
staining of EpEX and vimentin are visualized in confocal laser scanning microscopy for EpEX (green), vimentin 
(red) and as a merged image (combined colors). Nuclear DNA is stained in blue with DAPI. The margin 
between tumor and interstitium, and enlarged areas are marked as doted lines and solid squares. Cells with 
loss of EpCAM and gain of vimentin expression are marked with white arrows. Left panel: Depicts the edge 
of a tumor area; center panel: depicts vimentin-positive tumor cells at the edge of a tumor area; Right panel: 
depicts a small tumor island surrounded by interstitium, and rightmost panel: depicts two carcinoma cells 
demonstrating the co-localization of EpCAM+/vimentin− and EpCAM−/vimentin+ cells at the border to the 
interstitium.
www.nature.com/scientificreports/
6SCIeNtIfIC REpoRts |  (2018) 8:14582  | DOI:10.1038/s41598-018-32178-8
Figure 3. Association of single EpEX, Sox2 and vimentin IHC scores with clinical outcome in the LMU cohort. 
(a) Kaplan-Meier curves for the endpoints overall survival (OS), disease-free survival (DFS) and disease-specific 
survival (DSS) in HNSCC patients stratified according to HPV-status (HPV-positive versus HPV-negative). 
Hazard ratios (HR) with 95% confidence intervals (CI) and p-values (log-rank test) are indicated. (b,c) Kaplan-
Meier curves for overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) in 
HNSCC patients stratified into groups with low and high expression of EpEX, Sox2 and vimentin. Hazard ratios 
(HR) with 95% confidence intervals (CI), p-values (log-rank test) and the applied optimized threshold for the 
classification of patient subgroups are indicated for the entire cohort (b) and the HPV-negative sub-cohort (c).
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Optimized EpEX IHC score thresholds that maximized splits between high- and low expressors were thresh-
olds of 146.7, 66.7, and 111.7 for OS, DFS, and DSS hazard ratios, respectively (Fig. 3b). Optimized IHC score 
thresholds for Sox2 were 195, 40, and 33.4 for OS, DFS, and DSS hazard ratios, respectively (Fig. 3b) and that of 
vimentin were 150, 150, and 17.5 for OS, DFS, and DSS hazard ratios, respectively (Fig. 3b). In the LMU cohort 
(n = 94) irrespective of the HPV-status, EpEXhigh patients showed significantly improved DFS and DSS rates, and 
a strong tendency towards improved OS. Significantly enhanced OS, DFS, and DSS were observed for Sox2high 
classified patients (Fig. 3b). Vimentinlow classified patients showed a trend towards improved clinical outcome 
(Fig. 3b). Since EpEX and Sox2 expression levels were associated with HPV-status, which is known as strong 
prognostic factor in HNSCC, we further assessed the association of EpEX, Sox2 and vimentin in the subgroup of 
HPV-negative patients of the LMU cohort (n = 47). Both, EpEXhigh and Sox2high were significantly associated with 
enhanced OS, DFS, and DSS in HPV-negative patients (Fig. 3c).
Validation of the prognostic value of EpEx, Sox2 and vimentin. In order to independently ana-
lyze the prognostic value of EpEX, Sox2 and vimentin, expression levels of all three antigens were analyzed in 
an additional cohort of HNSCC that reflects the second major treatment regimen for HNSCC. The Göttingen 
validation cohort is composed of HNSCC samples (n = 94) from patients treated with definitive radio(chemo)
therapy without prior surgery owing to the presence of distant metastases already at initial diagnosis or due to 
unresectable tumors with respect to localization and size. Accordingly, patients within the Göttingen cohort had 
significantly more advanced tumors than patients in the LMU cohort (pT3–4 87.2% versus 43.6%; Chi-square 
p-value < 2 × 10−9), significantly more frequently locoregional lymph node metastases (pN + 83.0% versus 63.8%; 
Chi-square p-value < 0.01), significantly more often distant metastases (pM + 10.6% versus 1.1%; Chi-square 
p-value 0.01), and significantly differed in localization (Chi-square p-value 0.04), but did not significantly differ 
in their HPV-status (Tables 1 and 2). Taken together, these unfavorable clinical parameters resulted in worse 
outcome of patients in the Göttingen cohort. Expression of EpEX, Sox2, and vimentin was assessed in two to 
four punches per biospecimen on tissue micro-arrays of the validation cohort. Given the lack of primary surgery, 
influence of all three antigens on clinical endpoints in the presence of primary tumors can be assessed.
HPV-status was a prognostic factor for all clinical endpoints analyzed within the Göttingen cohort (Fig. 4a). 
Patients classified as EpEXhigh showed significantly enhanced DFS and a trend towards improved OS and DSS. 
Patients classified as Sox2high showed significantly enhanced OS, DFS, and DSS (Fig. 4b). Vimentinlow classified 
patients showed a tendency of slightly improved outcome (OS and DSS; Fig. 4b). EpEXhigh, but not Sox2high, was 
a prognosticator of significantly improved OS, DFS, and DSS in the subgroup of HPV-negative HNSCC patients 
within the Göttingen cohort (Fig. 4c). Sox2high HPV-negative patients showed a strong trend towards enhanced 
Variable Cohort Categories P-value
Sex Male Female
Göttingen 78 (83%) 16 (17%)
LMU 74 (78.7%) 20 (21.3%) 0,58
Age <50 50-69 ≥70
Göttingen 20 (21.3%) 63 (67%) 11 (11.7%)
LMU 15 (16%) 60 (63.8%) 19 (20.2%) 0,23
P16 negative positive
Göttingen 49 (52.1%) 45 (47.9%)
LMU 48 (62.3%) 29 (37.7%) 0,24
T-stage pT1-2 pT3-4 pTx
Göttingen 12 (12.8%) 82 (87.2%) 0 (0%)
LMU 51 (54.3%) 41 (43.6%) 2 (2.1%) <2 × 10−9
N-stage N0 N+ Nx
Göttingen 16 (17%) 78 (83%) 0 (17%)
LMU 1 (35.1%) 33 (63.8%) 60 (1.1%) <0.01
M-Stage cM0 cM+
Göttingen 93 (98.9%) 1 (1.1%)
LMU 84 (89.4%) 10 (10.6%) 0,01
Smoking Never Ever
Göttingen 18 (19.1%) 76 (80.9%)
LMU 14 (16.9%) 69 (83.1%) 0,84
Localization Oral Cavity Oropharynx Hypopharnyx/Larynx
Göttingen 30 (31.9%) 38 (40.4%) 26 (27.7%)
LMU 25 (26.6%) 54 (57.4%) 15 (16%) 0,04
Table 2. Statistical analysis of clinical parameters of HNSCC LMU and Göttingen cohorts (each n = 94) 
including gender, age, p16 expression, TNM status, smoking habits, and tumor sub-localization. Chi-square test 
was applied to calculate p-values.
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Figure 4. Association of single EpEX, Sox2 and vimentin IHC scores with clinical outcome in the Göttingen 
cohort. (a) Kaplan-Meier curves for the endpoints overall survival (OS), disease-free survival (DFS) and 
disease-specific survival (DSS) in HNSCC patients stratified according to HPV-status (HPV-positive versus 
HPV-negative). Hazard ratios (HR) with 95% confidence intervals (CI) and p-values (log-rank test) are 
indicated. (b,c) Kaplan-Meier curves for overall survival (OS), disease-free survival (DFS) and disease-specific 
survival (DSS) in HNSCC patients stratified into groups with low and high expression of EpEX, Sox2 and 
vimentin. Hazard ratios (HR) with 95% confidence intervals (CI), p-values (log-rank test) and the applied 
optimized threshold for the classification of patient subgroups are indicated for the entire cohort (b) and the 
HPV-negative sub-cohort (c).
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DSS (p = 0.057) (Fig. 4c). Thus, EpEXhigh distinguished HPV-negative patients with improved clinical outcome in 
the discovery and validation cohorts.
EpEX- and Sox2-based risk factor for the prediction of HNSCC clinical outcome. Since EpEX 
and Sox2 expression were prognostic in univariate analyses, we integrated measurements on both proteins in one 
multivariate cox proportional hazard model in order to calculate an integrated risk score for each patient. The 
cox model was fitted in the LMU cohort data (discovery cohort) followed by calculation of the risk scores and a 
median threshold, allowing assortment of patients into high- and low-risk. The fit coefficients and the threshold 
determined in the discovery cohort were used in combination with EpEX and Sox2 expressions measured in 
the validation cohort (Göttingen cohort) to calculate risk scores for subsequent assignment of patients of the 
Göttingen cohort to risk groups.
IHC scores of EpEX and Sox2 in relation to the risk score and Kaplan Meier plots are depicted for OS, DFS 
and DSS of the LMU cohort (Fig. 5a). Low risk score values reflected high expression levels of EpEX and Sox2, 
which were predictive of improved OS, DFS and DSS with hazard ratios of HR 0.44 (95% CI 0.2–0.96), 0.48 (95% 
CI 0.25–0.91), 0.23 (95% CI 0.05–1.13), and significant p-values (p = 0.034; p = 0.02; p = 0.048), for OS, DFS 
and DSS, respectively (Fig. 5a). The integrated risk score was furthermore prognostic for HPV-negative patients 
within the LMU cohort with respect to endpoints OS and DFS (Fig. 5a). In order to validate the risk score, we 
transferred the prognostic model that was developed using LMU data to data on the Göttingen cohort. Similarly, 
low risk score was associated with improved OS and DFS in the Göttingen cohort, thus confirming its prognostic 
power (Fig. 5b). However, the integrated risk factor was not prognostic for HPV-negative patients within the 
Göttingen cohort (Fig. 5b).
In a second set of analysis, the cox model was fitted within the HPV-negative LMU cohort data followed by 
calculation of the risk scores and a median threshold, allowing assortment of patients into high- and low-risk 
in the entire LMU cohort. IHC scores of EpEX and Sox2 in relation to the risk score and Kaplan Meier plots 
are depicted for OS, DFS and DSS of the LMU cohort (Fig. 6a). Low risk values (i.e. high levels of EpCAM and 
Sox2 in the HPV-negative LMU cohort) were predictive of improved DFS and DSS (HR 0.51, 95% CI 0.28–0.99, 
p = 0.043; HR 0.19, 95% CI 0.04–0.91, p = 0.02,  respectively). Furthermore, low risk values had a tendency to 
predict improved OS, however results were not statistically significant (HR 0.51, 95% CI 0.24–1.1, p = 0.08).
The fit coefficients and the threshold determined in the HPV-negative discovery cohort (LMU cohort) were 
transferred to the entire validation cohort (Göttingen cohort) to calculate risk scores for subsequent assignment 
Figure 5. Risk factor as a prognosticator for HNSCC. (a,b) Optimized thresholds for Sox2 and EpEX IHC 
scores were implemented in an integrated risk factor to predict the clinical outcome of HSNCCs. Shown is a 
heat-map representation of the composition of the risk factor across HNSCC patients of the LMU cohort  
(a; n = 94) and the Göttingen cohort (b; n = 94). Additionally, both cohorts were subdivided into HPV-negative 
sub-cohorts (right panels). Stratification of patients was conducted according to the SEV-factor into high and 
low scores. Overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) are depicted 
as Kaplan-Meier curves with hazard ratio (HR) at indicated 95% confidence interval (CI) and log-rank test 
p-values.
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of patients to risk groups (Fig. 6b). Low risk values were predictive of improved OS, DFS and DSS (HR 0.58, 95% 
CI 0.34–0.99, p = 0.043; HR 0.57, 95% CI 0.35–0.94, p = 0.02; HR 0.49, 95% CI 0.25–0.97, p = 0.036, respec-
tively). Lastly, both cohorts of HNSCC patients were pooled and stratified using the risk score generated in the 
HPV-negative LMU cohort. Low risk values were predictive of improved OS, DFS and DSS (HR 0.57, 95% CI 
0.38–0.87, p = 0.008; HR 0.59, 95% CI 0.41–0.87, p = 0.0062; HR 0.42, 95% CI 0.24–0.75, p = 0.0021, respec-
tively). Hence, risk scores based on EpCAM and Sox2 expression in HPV-negative HNSCC patients allow to 
stratify HNSCC patients independently of their HPV-status and treatment modality.
Discussion
HNSCC display outstandingly high inter- and intratumoral heterogeneity5,6 that might account for the high rate 
of radio(chemo)-resistance and treatment failure. Two aspects of cellular heterogeneity are considered central 
to tumor progression, treatment response and, thus, clinical outcome of carcinoma patients: (i) The presence of 
cancer stem cells (CSC) within primary tumors, which are considered the source of primary tumors, recurrences 
and metastatic outspread33, (ii) and phenotypic changes along the EMT, which facilitate tumor cell dissemination 
and metastases formation, and the induction of stemness8,9,11,12,34. One gene locus frequently affected by mutation 
in HNSCC is the SOX2 gene through amplification on chromosome 3q2630. Sox2 is a pluripotency factor that reg-
ulates HNSCC CSC fate through a PI3K/mTOR/Sox2/ALDH axis, which generates a tumor-initiating population 
with the capacity for asymmetric division and proliferation35. Furthermore, Sox2 fosters an epithelial phenotype 
in lung cancer, which has an etiology comparable to HNSCC with respect to risk factors, through enhanced tran-
scription of the pan-carcinoma marker EpCAM36. In line with this concept, loss of Sox2 expression in HNSCC 
resulted in up-regulated vimentin expression and migration, and reduced overall and progression-free survival30. 
Induction of EpCAM results in various cellular outcome including cell-cell adhesion37, enhanced tumor cell pro-
liferation19,38 and regulation of stem cell features20,39–41. Itself, EpCAM is prone to substantial regulation through-
out cancer progression27,42,43, stem cell differentiation22, and during EMT related to treatment resistance, e.g. in 
Figure 6. Risk factor as a prognosticator for HNSCC. (a–c) Optimized thresholds for Sox2 and EpEX IHC 
scores were implemented in an integrated risk factor to predict the clinical outcome of HSNCCs based on HPV-
negative patients of the LMU cohort. Overall survival (OS), disease-free survival (DFS) and disease-specific 
survival (DSS) are depicted as Kaplan-Meier curves with hazard ratio (HR) at indicated 95% confidence interval 
(CI) and log-rank test p-values for the entire LMU cohort (a), Göttingen cohort (b), and the pooled LMU and 
Göttingen cohort (c).
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prostate cancer26. Loss of EpCAM in mesodermally differentiating embryonic stem cells (ESC) during gastrula-
tion of mouse embryos is an early event initiating at E7.022. The resulting spatiotemporal patterning of EpCAM, 
with retention in endodermal but complete loss in mesodermal tissue, is mandatory for the completion of ESC 
differentiation22. Hence, loss of EpCAM in EMT and, generally, in mesenchymal differentiation is not only con-
comitant, but appears causal.
For the case of HNSCC, single cell RNA-sequencing data confirmed high inter- and intratumoral heteroge-
neity amongst tumor cells, but far less in associated stromal and immune cells32. Analysis of single cell transcrip-
tomes allowed to extract cell signatures defining cell cycle progression, hypoxia, cell stress, and epithelial and 
mesenchymal differentiation statuses in HNSCC32. The latter two signatures were inversely correlated and charac-
terized, amongst others, by high-level EpCAM and vimentin/slug expressions, respectively. Hence, EpCAM rep-
resents an excellent measure for the level of epithelial differentiation of carcinoma cells in head and neck tumors, 
whereas vimentin depicts a gradual mesenchymal switch. These molecular networks with reported functionality 
in tumor progression and treatment resistance prompted us to investigate protein co-expression levels and pat-
terns of Sox2, EpCAM and vimentin in HNSCC. For all three antigens, inter- and intratumoral heterogeneity 
was observed, which translated into different clinical outcome. Low expression of Sox2 significantly correlated 
with poor OS, DFS and DSS in an univariate analysis within our discovery cohort, which is confirmatory of Bayo 
et al.30. Similarly, Chung et al. and Bochen et al. reported on a positive prognostic value of high-level expression 
of Sox2 in HNSCC44,45. However, contradicting results have been reported too, such that HNSCC patients with 
high-level Sox2 expression were characterized by poorer outcome46, as well as a complete lack of prognostic value 
of Sox2 in HNSCC47. Our own findings clearly are in support of a beneficial effect of high-level Sox2 expression 
on clinical outcome.
Low expression of epithelial marker EpCAM significantly correlated with decreased DFS and DSS (univari-
ate). These findings contradict the reported poor prognosis of breast, colorectal, pancreatic, ovarian and bladder 
cancers over-expressing EpCAM48–56, but is in line with the association of high levels of EpCAM with improved 
prognosis of colonic, gastric and renal cancer57–59. We further confirmed our findings in a validation cohort com-
posed of biospecimen obtained from HNSCC patients treated with primary radio(chemo)therapy. Limitations 
must be noted, as patients within the validation cohort were characterized by the presence of significantly larger 
tumors and generally more advanced disease, including increased locoregional and distant metastases (Table 2). 
Expectedly, these patients were confronted with substantially poorer outcome than patients included in the LMU 
cohort. Furthermore, EpCAM expression was assessed with two distinct monoclonal antibodies with slightly 
differing binding affinities (Vu1D9 > Ber-Ep4; own unpublished data), which might affect the quantification of 
antigen levels and explain generally lower levels of EpCAM in the Göttingen cohort. Nonetheless, EpCAM and 
Sox2 possessed prognostic value, even under these testing conditions and in the presence of the primary tumor 
throughout the observation period (Göttingen cohort). Hence, we could show that EpEXhigh and Sox2high are 
prognosticators of improved clinical outcome in two independent, retrospective clinical cohorts despite limi-
tations and challenges arising from differing clinical cohorts and staining procedures. Both cohorts cover both 
major clinical treatment modalities and staining procedures (cryopreserved native samples versus FFPE routine 
staining), and should as such allow for more generalized findings.
Generally, our findings suggest that an epithelial, proliferative Sox2high/EpCAMhigh phenotype of HNSCC 
could foster survival, which might be based on enhanced therapy response. Oppositely, loss of epithelial traits dur-
ing partial EMT, as measured by EpCAM reduction and gain in vimentin32, might be associated with decreased 
proliferation and increased migration, or primarily with increased treatment resistance as demonstrated for pros-
tate, pancreatic, breast cancer and HNSCC15,16,26,32. Both features can promote reduced radio(chemo)sensitivity 
and increased local invasion, which represent potential sources of recurrence and locoregional spread, which is a 
common and frequent feature of HNSCC1.
HPV infection is an accepted clinical factor for HNSCC60 that predicts improved outcome and has been 
implemented in the AJCC 8th edition of the TNM classification of patients4,61. Although HPV-status as such is 
an important stratificator it is currently only used to distinguish two separate HNSCC entities for diagnostic/
prognostic purposes, while its actual use for therapeutic stratification in routine remains under investigation 
in several clinical studies (RTOG 3311, NRG HN002). Furthermore, it currently leaves HPV-negative HNSCC 
patients without any further stratification options except for the TNM status and extracapsular extension. In this 
respect, EpEXhigh qualifies as a candidate to stratify HPV-negative HNSCC into further prognostic groups. In fact, 
HPV-negative patients with high levels of EpCAM displayed improved survival rates for all tested clinical end-
points that were similar to that of the HPV-positive subgroup. Thus, EpEXhigh bears the potential as a prognostic 
biomarker for HPV-negative HNSCC patients.
In a further step, we combined EpEX and Sox2 levels in an integrated risk factor. We deliberately did not 
include HPV as a parameter in the risk model owing to its impact as a strong prognostic factor in HNSCC, 
which might result in a risk factor that predicts HPV rather than survival. This is demonstrated by a very strong 
association (p < 10−12, not HPV-stratified LMU cohort, p < 2.2−16 not HPV-stratified Göttingen cohort, Fisher’s 
exact test) of HPV status with the risk factor generated including HPV-status and a much weaker association 
when not including HPV (p = 0.17, not HPV-stratified LMU cohort, 0.045 not HPV-stratified Göttingen cohort, 
Fisher’s exact test). In contrast, we were aiming to test whether EpCAM and Sox2 in combination are able to 
predict survival independent of HPV. Both EpCAM and Sox2 are only weakly associated with HPV status in 
the LMU cohort but not in the Göttingen cohort (p-values LMU: EpCAM 0.01, Sox2: 0.02, Göttingen: EpCAM 
0.36, Sox2: 0.12). This suggests that Sox2 and EpCAM expressions are somewhat but not strongly influenced by 
HPV, and hence are not a strong proxy of the HPV status. Consequently, we assumed that a risk score integrat-
ing Sox2 and EpCAM but not HPV should be able to predict clinical outcome independently of HPV. In fact, 
the integrated risk score that combined measurements on Sox2 and EpEX expression levels significantly pre-
dicted outcome with respect to OS, DFS and DSS in both non-HPV stratified cohorts. Sox2high/EpEXhigh defined 
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patients with better outcome, both, after standard therapy involving surgery and adjuvant radio-chemotherapy, 
as well as after primary radio(chemo)therapy in the absence of prior surgical tumor resection. Both therapeu-
tic strategies represent the two major treatment regimens and, thus, the risk score is applicable to the majority 
of clinical HNSCC cases. Additionally, Sox2 and EpCAM are common antigens for the automated staining of 
formalin-fixed, paraffin-embedded specimen, which would allow for comparably simple assessment in clinical 
routine. It must be noted that the integrated risk score was characterized by hazard ratios and p-values similar 
to univariate analyses of EpEX and Sox2 in both cohorts. However, although the integrated risk score does not 
outperform single EpEX and Sox2 scores with respect to prognostic power, implementing two or even more inde-
pendent measurements within one risk score could contribute to improve the reliability of prognosis and ease 
handling of otherwise singular score values in clinical routine.
Additionally, in order to rule out a contribution of the HPV-status to the risk score, the cox model to deter-
mine thresholds for optimized stratification splits was fitted within the HPV-negative patients of the discovery 
cohort. The determined risk scores were then applied to the entire discovery and validation cohorts as well as 
to a pooled cohort composed of both separate cohorts. By doing so, we demonstrated that risk scores based on 
EpCAM and Sox2 expression generated in HPV-negative patients have the potential to predict clinical endpoints 
such as OS, DFS, and DSS independently of the HPV-status of the patient and of differential treatment regimens.
The integrated risk score could be assessed from pre-operative biopsies at the time point of first diagnosis and 
serve as an additional molecular parameter. Together with other clinical parameters such as resection margins 
and extracapsular extension, it could help to identify high-risk situations and, thus, the need for intensification 
of multimodal therapy.
In summary, the integrated risk factor, and EpEXhigh more specifically, presented herein have the potential to 
contribute to improve HNSCC stratification of HNSCC patients, including HPV-negative cases, and might open 
novel options for therapy decisions.
Methods
Human biospecimen. Biospecimen are reported according to BRISQ and REMARK standards62. The 
Ludwig-Maximilians-University of Munich (LMU) cohort (discovery cohort) is composed of 94 patients with 
HNSCC of whom tumor biomaterial has been collected. The cohort comprises primary tumors (n = 81), recur-
rences (n = 3), residual carcinoma (n = 1) and secondary carcinomas of the head and neck (n = 9). Furthermore, 
distant normal mucosa and tumor-adjacent normal mucosa were available for 87 and 19 of these patients, respec-
tively. Patients were treated with surgery and adjuvant radio(chemo)therapy upon indication. Age, sex, tumor 
localization, smoking habits, TNM and p16 status, as a surrogate marker for HPV infection63,64, are compiled 
in Table 1. P16 status will be referred to as HPV-status in the following. The most prevalent HNSCC subgroup 
within the cohort comprised oropharyngeal squamous carcinomas (57.4%), with 30.9% HPV-positive samples, 
thus conforming to overall frequencies worldwide65. All patients of the LMU cohort received surgical treatment 
and adjuvant radiotherapy (radiation doses: 50.4–70 Gy; mean 63.07 Gy; median 64.0 Gy; three patients obtained 
increased doses up to 70 Gy based on clinical requirements such as uncertain resection margins with residual 
tumor in situ) with or without simultaneous chemotherapy. Most patients received cisplatin/5-fluorouracil 
(CDDP/5-FU). In selected cases, mitomycin C (MMC), 5-FU/MMC, or Cetuximab replaced platin-based chemo-
therapy. Macroscopically normal mucosa was obtained after surgical removal of the primary tumor beyond the 
resection margins with >5 mm distance to the initial tumor bed. Tumor-adjacent mucosa was defined as areas of 
histologically normally structured but hyper- to dysplastic epithelium in the close vicinity of tumor fields. All bio-
specimens were stabilized through embedment in tissue-Tek® (Sakura, Finetek, The Netherlands), snap-frozen 
in liquid nitrogen, and preserved at −80 °C before further processing.
The Göttingen cohort (validation cohort) is composed of 94 patients with HNSCC, who received definitive 
radiotherapy with or without simultaneous chemotherapy. The cohort comprises 94 primary tumors. Age, sex, 
tumor localization, smoking habits, TNM and p16 status are compiled in Table 1. Intended total radiation dose 
in this primary setting was 70.0 and 66.0 for 87 and 7 patients, respectively. Complete radiation as planned was 
administered in 85 individuals (90.4%); total dose was reduced in six patients by <10.0 and in three by 10.0–
20.0 Gy due to medical reasons or according to patient willingness. Concomitant chemotherapy was given in 75 
out of the 94 patients of whom 41 received 5-FU/MMC, 30 cisplatin as single agent, and four received Cetuximab. 
Biospecimens of the Göttingen cohort were formalin-fixed and paraffin-embedded before processing as tissue 
microarrays.
Immunohistochemistry and immunofluorescence staining. Immunohistochemistry intensity scores 
(IHC score) were calculated as the product of intensity (0 to 3 +) and percentage of expressing tumor cells within 
biospecimens. IHC scores represent averages of values independently assessed by minimum two experimenters, 
who were blinded with respect to clinical staging and outcome of patients. Staining was analyzed separately for 
each individual antigen in order to preclude potential bias with respect to correlation of antigen expression. 
Antigen expression in the LMU cohort was assessed in 2–4 sections (≥10 × 10 mm) of primary specimens and 
represented average IHC scores across all entire sections considering tumor areas only. Antigen expression in the 
Göttingen cohort was assessed in tissue microarrays of biopsies from primary tumor specimens and represented 
the average of 2–4 punches of 1.5 mm diameter taken randomly from different regions within each specimen. The 
comparably large size of sample within the LMU cohort and the number of punches and diversity of areas for 
samples within the Göttingen cohort were chosen to allow for the most adequate coverage of tumor heterogeneity.
EpEX- (LMU cohort: VU1D9, Cell Signaling Technology, NEB, Frankfurt, Germany, #2929; Göttingen cohort: 
Ber-Ep4, Dako, Hamburg, Germany, #M080429), Sox2- (D6D9, Cell Signaling Technology, NEB, Frankfurt, 
Germany, #3579), vimentin- (3B4, Dako, Hamburg, Germany, #M702001), CD31- (JC70A, Dako, Hamburg, 
Germany, #IR61061), CD68- (KP1, Dako, Hamburg, Germany, #M081401), and CD90-specific antibodies 
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(2Q1469, DCS Immuno Line, Hamburg, Germany, #CI921C002) were used for immunohistochemistry and 
immunofluorescence detection of antigens. Immunostaining was performed using the avidin-biotin-peroxidase 
method (Vectastain, Vector laboratories, Burlingame, CA, USA) according to the manufacturers’ protocol. For 
immunofluorescence, Alexa Fluor®−488- and Alexa Fluor®−594-conjugated secondary antibodies were used to 
visualize specific primary antibodies. Laser scanning confocal microscopy images were recorded with a TCS-SP5 
system (Leica Microsystems; Wetzlar, Germany).
Clinical endpoints and survival analysis. Overall survival (OS), disease-free survival (DFS) and 
disease-specific survival (DSS) were chosen as clinical endpoints. We calculated OS (months) from the date of 
diagnosis to death due to any cause, DFS to the first observation of any recurrence or death, and DSS to the date 
of HNSCC-related death. In the absence of an event, patients were censored at the date of the last follow-up visit.
Data analysis was performed in R (R Core Team, R: A Language and Environment for Statistical Computing, 
R Foundation for Statistical Computing, 2017; version 3.4.0) in combination with R-survival package (CRAN). 
For univariate analysis, the IHC expression scores were included into cox-proportional hazard models after bina-
rization into high- and low expressors. The threshold for binarization was the value picked from the whole range 
of expression scores that resulted in a maximum split of high- and low-expressors with regard to hazard-ratio. In 
order to prevent artificially extreme hazard-ratios resulting from very small groups only thresholds were allowed 
that split patients in groups containing at least 5 patients. Hazard ratios, 95% confidence interval ratios, median 
survival times and log-rank p-values were calculated and included in Kaplan-Meier plots. In order to generate 
prognostic models integrating EpEX and Sox2, in a first step a multivariate model was built with the contin-
uous expression values of the two proteins included as covariates. The resulting fit coefficients were extracted 
from the model and multiplied with the appropriate expression values of each patient before building the sum, 
which was then used as risk score. The risk scores were binarised into high- and low-risk by a threshold that was 
maximized for hazard-ratio as described above. Hazard ratios, 95% confidence interval ratios, median survival 
times and log-rank p-values were calculated and included in Kaplan-Meier plots along with distribution plots 
of risk scores and expression heatmaps. Statistical tests for all figures are justified as appropriate. Visual inspec-
tion of distribution shapes of comparison groups revealed no obvious differences. Normality was tested with the 
Kolgomorov-Smirnov test and assumptions for the test were met. Equal variances between the groups were tested 
using the Levene test with no differences observed.
Analysis of the TCGA HNSCC cohort. The results are based upon data generated by the TCGA Research 
Network: http://cancergenome.nih.gov. mRNA expression level z-scores for EpCAM, Sox2 and Vimentin were 
downloaded for the Nature published HNSCC TCGA cohort (n = 279) at cBioPortal5,66,67. Spearman correlation 
analyses of mRNA expression z-scores were performed, and results were considered statistically significant when 
p < 0.05.
Ethics approval and consent to participate. All clinical samples were obtained after written informed 
consent during routine surgery or biopsy based on the approval by the ethics committee of the local medical 
faculties (Ethikkomission der Medizinischen Fakultät der Ludwig-Maximilians-Universität; #087-03; #197-11; 
#426-11; Ethikkomission der Medizinischen Fakultät der Universität Göttingen; #7/4/2012) and in compliance 
with the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
Availability of Data and Material
Data availability is restricted as required by the ethics obligations and relevant medical and legal issues.
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